Headache and Migraine

The associate professor in the department of radiology at NYU Langone provided perspective on the unanswered questions regarding neuronal microstructure in migraine following her presentation at the 2024 AAN Annual Meeting. [WATCH TIME: 4 minutes]

The director of the MedStar Georgetown Headache Center talked about results from an analysis on the DELIVER study assessing response rates of eptinezumab in patients with migraine over an 18-month period.

The director of Dysautonomia Clinic talked about advocating for recognition and research into neurological symptoms that have long been overlooked in patients with Long COVID. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on cluster headache.

ABP-450, a botulinum toxin type A complex agent, failed to meet either primary or secondary end points in a cohort of 325 patients with chronic migraine.

Catch up on any of the neurology news headlines you may have missed over the course of April 2024, compiled all into one place by the NeurologyLive® team.

STS101 demonstrated mild and predictable adverse events, suggesting potential efficacy at 5.2 mg dose for migraines.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on treatment-refractory epilepsy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on primary progressive aphasia.

Stephen Samples, MD, chair of Allegheny Health Network’s department of neurology, gave commentary towards the AHS’s recent statement paper addressing CGRP-targeting therapies as a first-line option for preventive migraine.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the sleep disorders.

Neurology News Network. for the week ending April 20, 2024. [WATCH TIME: 3 minutes]

Across 2, phase 3 studies, fremanezumab provided significant effects on monthly migraine days, regardless of whether patients were obese or not.

Combination of atogepant and ubrogepant resulted in minimal adverse events, and were safe and well-tolerated over a 12-week period.

Results showed consistent reductions in monthly migraine days over 48 weeks, with a favorable safety profile observed.

The medical director of the Weill Cornell Medicine Headache Program discussed key essential knowledge on the diagnosis, treatment, and pathophysiology of different headache types. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the American Academy of Neurology Annual Meeting.

In the phase 3 MOMENTUM and INTERCEPT studies, patients treated with AXS-07 saw reductions in headache pain freedom, most bothersome symptoms, and use of rescue medications.

Being a boy, having lower depression and anxiety scores, lower headache intensity, lower affective pain perception, fewer pain locations, fewer sleep issues, and lower pain-related disability predicted headache remission.

The new position statement proposes the use of CGRP-targeting therapies to be used as first-line treatments, eliminating the need to fail multiple medications before access.

The director of Dysautonomia Clinic discussed neurological manifestations of Long COVID, such as headache, cognitive complaints, and sleep problems, and how they are similar to those seen with migraine comorbidities. [WATCH TIME: 5 minutes]

Therapeutic effects were noticeable within 15–20 days post-injection, with five of six patients achieving complete pain relief.

Here's some of what is coming soon to NeurologyLive® this week.

The presence of a sleep disorder was associated with a nearly 2-fold increase in the risk of increased health care utilization, with specific odds associated with individual sleep disorders.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on limb girdle muscular dystrophy.